Novo Nordisk is a big company in Denmark that makes medicines to help people with diabetes and obesity. They also make some proteins for people with bleeding problems. Their medicine price has gone up a little bit, but they are expected to make more money soon. Some experts think their stock will be worth more than it is now. People who trade options on this company need to be careful because there are risks involved, but also chances to make money. Benzinga helps them stay informed and trade smarter by giving them news and data about Novo Nordisk. Read from source...

1. The author fails to provide a clear definition of what constitutes a surge in options activity and how it is measured. This makes the entire premise of the article vague and unreliable as a source of information for investors or traders.

Given the information provided, I would suggest considering Novo Nordisk as a long-term investment option due to its strong market position, diversified product portfolio, and potential for future growth in diabetes care and obesity treatments. However, there are some risks involved such as increased competition from generic insulin products, regulatory changes that may affect the pricing and availability of their products, and the possibility of adverse clinical trial results or safety concerns. Therefore, it is important to monitor the developments in these areas closely and adjust your investment strategy accordingly. Additionally, given the high valuation of Novo Nordisk's stock based on the average price target of $160 per share, you may want to consider setting a stop-loss order at around 10% below the current market price to limit your potential losses if the stock price declines significantly.